Vijay Kumar Ulaganathan

Vijay Kumar Ulaganathan

Auto-generated profile, based on publicly available information

Vijay Kumar Ulaganathan

Institute of Medical Genetics and Applied Genomics University Hospital Tübingen Tübingen Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2012 in Nature
Verified
Journal Article
Closed access
FOFrancesca Odoardi
Francesca Odoardi
CSChristopher Sie
Christopher Sie
KSKristina Streyl
Kristina Streyl
VUVijay K. Ulaganathan
Vijay K. Ulaganathan
CSChristian Schläger
Christian Schläger
AFAlexander Flügel
Alexander Flügel

16 December 2015 in Nature
Verified
Journal Article
Closed access
VUVijay K. Ulaganathan
Vijay K. Ulaganathan
BSBianca Sperl
Bianca Sperl
URUlf R. Rapp
Ulf R. Rapp
AUAxel Ullrich
Axel Ullrich

2 June 2010 in Brain
Verified
Journal Article
Open access
PDF file
CCChiara Cordiglieri
Chiara Cordiglieri
FOFrancesca Odoardi
Francesca Odoardi
BZBo Zhang
Bo Zhang
MNMerle Nebel
Merle Nebel
NKNaoto Kawakami
Naoto Kawakami
AFAlexander Flügel
Alexander Flügel
Nicotinic acid adenine dinucleotide phosphate represents a newly identified second messenger in T cells involved in antigen receptor-mediated calcium signalling. Its function in vivo is, however, unknown due to the lack of biocompatible inhibitors. Using a recently developed inhibitor, we explored the role of nicotinic acid adenine dinucleotide phosphate in autoreactive effector T cells during experimental autoimmune encephalomyelitis, the animal model for multiple sclerosis. We provide in vitro and in vivo evidence that calcium signalling controlled by nicotinic acid adenine dinucleotide phosphate is relevant for the pathogenic potential of autoimmune effector T cells. Live two photon imaging and molecular analyses revealed that nicotinic acid adenine dinucleotide phosphate signalling regulates T cell motility and re-activation upon arrival in the nervous tissues. Treatment with the nicotinic acid adenine dinucleotide phosphate inhibitor significantly reduced both the number of stable arrests of effector T cells and their invasive capacity. The levels of pro-inflammatory cytokines interferon-gamma and interleukin-17 were strongly diminished. Consecutively, the clinical symptoms of experimental autoimmune encephalomyelitis were ameliorated. In vitro, antigen-triggered T cell proliferation and cytokine production were evenly suppressed. These inhibitory effects were reversible: after wash-out of the nicotinic acid adenine dinucleotide phosphate antagonist, the effector T cells fully regained their functions. The nicotinic acid derivative BZ194 induced this transient state of non-responsiveness specifically in post-activated effector T cells. Naïve and long-lived memory T cells, which express lower levels of the putative nicotinic acid adenine dinucleotide phosphate receptor, type 1 ryanodine receptor, were not targeted. T cell priming and recall responses in vivo were not reduced. These data indicate that the nicotinic acid adenine dinucleotide phosphate/calcium signalling pathway is essential for the recruitment and the activation of autoaggressive effector T cells within their target organ. Interference with this signalling pathway suppresses the formation of autoimmune inflammatory lesions and thus might qualify as a novel strategy for the treatment of T cell mediated autoimmune diseases.

1 January 2013 in Clinica Chimica Acta
Verified
Journal Article
Closed access
SLSimon Lytton
Simon Lytton
EAEmiliano Antiga
Emiliano Antiga
SPSascha Pfeiffer
Sascha Pfeiffer
TMTorsten Matthias
Torsten Matthias
ASAnna Szaflarska-Poplawska
Anna Szaflarska-Poplawska
MCMarzia Caproni
Marzia Caproni

3 April 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DKDaniel Kogan
Daniel Kogan
AGAlexander Grabner
Alexander Grabner
CYChristopher Yanucil
Christopher Yanucil
CFChristian Faul
Christian Faul
VUVijay Kumar Ulaganathan
Vijay Kumar Ulaganathan
Immune evasion and the suppression of antitumor responses during cancer progression are considered hallmarks of cancer and are typically attributed to tumor-derived factors. Although the molecular basis for the crosstalk between tumor and immune cells is an area of active investigation, whether host-specific germline variants can dictate immunosuppressive mechanisms has remained a challenge to address. A commonly occurring germline mutation (c.1162G>A/rs351855 G/A) in the FGFR4 (CD334) gene enhances signal transducer and activator of transcription 3 (STAT3) signaling and is associated with poor prognosis and accelerated progression of multiple cancer types. Here, using rs351855 SNP–knockin transgenic mice and Fgfr4-knockout mice, we reveal the genotype-specific gain of immunological function of suppressing the CD8/CD4+FOXP3+CD25+ regulatory T cell ratio in vivo. Furthermore, using knockin transgenic mouse models for lung and breast cancers, we establish the host-specific, tumor-extrinsic functions of STAT3-enhancing germline variants in impeding the tumor infiltration of CD8 T cells. Thus, STAT3-enhancing germline receptor variants contribute to immune evasion through their pleiotropic functions in immune cells.

1 December 2014 in Translational Oncology
Verified
Journal Article
Open access
FKFlorian Kopp
Florian Kopp
AHAdam Hermawan
Adam Hermawan
POPrajakta Shirish Oak
Prajakta Shirish Oak
VUVijay Kumar Ulaganathan
Vijay Kumar Ulaganathan
AHAnnika Herrmann
Annika Herrmann
ARAndreas Roidl
Andreas Roidl
Acquiring therapy resistance is one of the major obstacles in the treatment of patients with cancer. The discovery of the cancer stem cell (CSC)-specific drug salinomycin raised hope for improved treatment options by targeting therapy-refractory CSCs and mesenchymal cancer cells. However, the occurrence of an acquired salinomycin resistance in tumor cells remains elusive. To study the formation of salinomycin resistance, mesenchymal breast cancer cells were sequentially treated with salinomycin in an in vitro cell culture assay, and the resulting differences in gene expression and salinomycin susceptibility were analyzed. We demonstrated that long-term salinomycin treatment of mesenchymal cancer cells resulted in salinomycin-resistant cells with elevated levels of epithelial markers, such as E-cadherin and miR-200c, a decreased migratory capability, and a higher susceptibility to the classic chemotherapeutic drug doxorubicin. The formation of salinomycin resistance through the acquisition of epithelial traits was further validated by inducing mesenchymal-epithelial transition through an overexpression of miR-200c. The transition from a mesenchymal to a more epithelial-like phenotype of salinomycin-treated tumor cells was moreover confirmed in vivo, using syngeneic and, for the first time, transgenic mouse tumor models. These results suggest that the acquisition of salinomycin resistance through the clonal selection of epithelial-like cancer cells could become exploited for improved cancer therapies by antagonizing the tumor-progressive effects of epithelial-mesenchymal transition.